Table 1.
Demographics and baseline characteristics of the study cohort (N = 632)
| Baseline characteristics (N = 632) | N (%) |
|---|---|
| Gender | |
| Male | 420 (66.5%) |
| Female | 212 (33.5%) |
| Race | |
| White | 559 (88.4%) |
| African America | 27 (4.3%) |
| Hispanic | 10(1.6%) |
| Other/unknown | 36 (5.7%) |
| Age at diagnosis | |
| <60 years | 87 (13.8%) |
| ≥60 years | 545 (86.2%) |
| Therapy-related MDS | |
| Yes | 181 (28.6%) |
| No | 451 (71.4%) |
| WHO classification | |
| RA or RCUD | 19 (3.0%) |
| RARS | 12 (1.9%) |
| RCMD | 74 (11.7%) |
| RAEB-1 | 167 (26.5%) |
| RAEB-2 | 349 (55.2%) |
| MDS-NOS | 10 (1.6%) |
| 5q-MDS | 1 (0.1%) |
| IPSS risk group | |
| Intermediate-2 | 440 (69.6%) |
| High | 192 (30.4%) |
| IPSS cytogenetic risk group | |
| Good | 140 (22.2%) |
| Intermediate | 128 (20.2%) |
| Poor | 364 (57.6%) |
| RBC transfusion dependence | |
| Yes | 397 (62.8%) |
| No | 235 (37.2%) |
| Platelet transfusion dependence | |
| Yes | 286 (45.3%) |
| No | 346 (54.7%) |
| ECOG PS | |
| 0 | 131 (20.7%) |
| 1 | 440 (69.6%) |
| 2 | 57 (9.0%) |
| 3 | 3 (0.5%) |
| 4 | 1 (0.2%) |
| Institution | |
| H. Lee Moffitt Cancer Center | 245 (38.8%) |
| Cleveland Clinic | 87 (13.8%) |
| Dana-Farber Cancer Institute | 39 (6.2%) |
| Weill Medical College of Cornell University | 66 (10.4%) |
| MD Anderson Cancer Center | 170 (26.9%) |
| Johns Hopkins University | 25 (4.0%) |
| Type of azanucleoside | |
| Azacitidine | 429 (67.9%) |
| Decitabine | 203 (32.1%) |
Abbreviations: ECOG PS, Eastern Cooperative Cancer Group performance status; IPSS, International Prognostic Scoring System; MDS, myeldysplastic syndrome; NOS, non-otherwise-specified; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ring sideroblasts; RBC, red blood cells; RCMD, refractory cytopenia(s) with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; WHO, World Health Organization; 5q-, deletion of chromosome 5q.